CAMP4 Therapeutics (CAMP) vs Lyell Immunopharma (LYEL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
CAMP4 Therapeutics (CAMP) has outperformed Lyell Immunopharma (LYEL) over the past year, gaining 8.2% versus a loss of 50.8%. Lyell Immunopharma is the larger company by market cap ($199.0 million vs $198.9 million), about 1.0 times the size, while CAMP4 Therapeutics is growing revenue faster (+436.5% vs -41.0%). CAMP4 Therapeutics converts more of its revenue into profit, with a net margin of -2298.5% versus -762355.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CAMP | LYEL |
|---|---|---|
| Share price | $3.17 | $8.12 |
| Market cap | $198.93M | $198.98M |
| 1-day change | -8.12% | -0.85% |
| YTD return | -48.29% | -73.62% |
| 1-year return | +8.19% | -50.79% |
| 5-year return | — | -97.06% |
| EPS (TTM) | $-2.35 | $-12.86 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $3.50M | $36.00K |
| Revenue growth (YoY) | +436.50% | -40.98% |
| Net income (latest FY) | $-80.40M | $-274.45M |
| Operating margin | -1502.43% | -748344.44% |
| Net margin | -2298.54% | -762355.56% |
| 52-week high | $7.75 | $45.00 |
| 52-week low | $2.88 | $7.20 |
| Distance from 52-week high | -59.10% | -81.96% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +233.44% | +366.50% |
| Average volume | 267.29K | 152.61K |
| Shares outstanding | 62.75M | 24.51M |
| Employees | 48 | 161 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CAMP has outperformed LYEL by 59.0 percentage points over the past year.
- CAMP4 Therapeutics is more profitable, keeping -2298.5 cents of every revenue dollar as net income versus -762355.6 cents for Lyell Immunopharma.
- CAMP4 Therapeutics grew revenue faster in its latest fiscal year (+436.50% vs -40.98%).
About CAMP4 Therapeutics
CAMP stock →Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-001, which is in a Phase 1/2 clinical trial for the treatment of urea cycle disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 48 employees
About Lyell Immunopharma
LYEL stock →Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company's lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial, PiNACLE-H2H, which is a Phase 3 head-to-head CAR T cell therapy randomized controlled trial of ronde-cel for LBCL in the 2L setting for the treatment of large B-cell lymphoma; and LYL273, a GCC-targeted CAR T-cell product candidate enhanced with CD19 CAR expression and controlled cytokine release designed to improve CAR T-cell expansion, immune cell infiltration, and cancer cell killing in the hostile solid tumor microenvironment, which is in Phase 1 clinical trial for the treatment of refractory metastatic colorectal cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 161 employees
CAMP vs LYEL FAQ
Which is bigger, CAMP4 Therapeutics or Lyell Immunopharma?
Lyell Immunopharma (LYEL) is larger, with a market capitalization of $198.98M compared with $198.93M for CAMP4 Therapeutics (CAMP).
Which stock has performed better over the past year, CAMP or LYEL?
CAMP returned +8.19% over the past 12 months, compared with -50.79% for LYEL (price return, excluding dividends). Past performance does not predict future results.
Are CAMP4 Therapeutics and Lyell Immunopharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.